OTCPK:CPPS.F

Stock Analysis Report

Executive Summary

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide.


Snowflake Analysis

Exceptional growth potential with mediocre balance sheet.

Share Price & News

How has Cassiopea's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CPPS.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

CPPS.F

-4.1%

US Pharmaceuticals

-7.4%

US Market


1 Year Return

n/a

CPPS.F

2.0%

US Pharmaceuticals

10.5%

US Market

Return vs Industry: Insufficient data to determine how CPPS.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CPPS.F performed against the US Market.


Shareholder returns

CPPS.FIndustryMarket
7 Day0%-4.1%-7.4%
30 Day0%-5.0%-3.6%
90 Dayn/a0.6%-0.6%
1 Yearn/a4.6%2.0%12.8%10.5%
3 Yearn/a20.1%11.5%37.4%28.6%
5 Yearn/a23.7%10.1%61.3%43.6%

Price Volatility Vs. Market

How volatile is Cassiopea's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cassiopea undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CPPS.F ($43.5) is trading below our estimate of fair value ($633.19)

Significantly Below Fair Value: CPPS.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CPPS.F is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: CPPS.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CPPS.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CPPS.F is overvalued based on its PB Ratio (45.2x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Cassiopea forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

52.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPPS.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: CPPS.F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CPPS.F's is expected to become profitable in the next 3 years.

Revenue vs Market: CPPS.F's revenue (53% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: CPPS.F's revenue (53% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CPPS.F's Return on Equity is forecast to be very high in 3 years time (3367.4%).


Next Steps

Past Performance

How has Cassiopea performed over the past 5 years?

-23.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPPS.F is currently unprofitable.

Growing Profit Margin: CPPS.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CPPS.F is unprofitable, and losses have increased over the past 5 years at a rate of -23% per year.

Accelerating Growth: Unable to compare CPPS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CPPS.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).


Return on Equity

High ROE: CPPS.F has a negative Return on Equity (-146.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cassiopea's financial position?


Financial Position Analysis

Short Term Liabilities: CPPS.F's short term assets (€2.9M) exceed its short term liabilities (€1.9M).

Long Term Liabilities: CPPS.F's short term assets (€2.9M) exceed its long term liabilities (€2.2M).


Debt to Equity History and Analysis

Debt Level: CPPS.F's debt to equity ratio (25.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CPPS.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: CPPS.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: CPPS.F's debt is covered by short term assets (assets are 1.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CPPS.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CPPS.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.4% each year


Next Steps

Dividend

What is Cassiopea's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CPPS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CPPS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPPS.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPPS.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CPPS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Diana Harbort (53yo)

5.1yrs

Tenure

€276,152

Compensation

Ms. Diana Harbort serves as the Chief Executive Officer of Cassiopea S.p.A. since 2015 and has been its Executive Director since May 2015. Ms. Harbort served as the Head of Corporate Development at Medicis ...


CEO Compensation Analysis

Compensation vs Market: Diana's total compensation ($USD300.43K) is below average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Diana's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Diana Harbort
CEO & Executive Director5.1yrs€276.15kno data
Hans Tanner
CFO & Head of Investor Relations5.1yrsno datano data
Marco Pasero
Chief Operating Officer5.1yrsno datano data
Luigi Moro
Chief Scientific Officer0yrsno datano data
Alessandro Mazzetti
Chief Medical Officer3.1yrsno datano data
Marco Lecchi
Finance Director0yrsno datano data
Sheetal Sahel
Vice President of Marketing1.1yrsno datano data
Dave Wood
Vice President of Sales0yrsno datano data

5.1yrs

Average Tenure

61yo

Average Age

Experienced Management: CPPS.F's management team is seasoned and experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cassiopea S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cassiopea S.p.A.
  • Ticker: CPPS.F
  • Exchange: OTCPK
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF407.000m
  • Listing Market Cap: CHF417.055m
  • Shares outstanding: 10.00m
  • Website: https://www.cassiopea.com

Number of Employees


Location

  • Cassiopea S.p.A.
  • Via Cristoforo Colombo, 1
  • Lainate
  • Milan
  • 20020
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SKINSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFJul 2015
0R8YLSE (London Stock Exchange)YesRegistered SharesGBCHFJul 2015
CSPDB (Deutsche Boerse AG)YesRegistered SharesDEEURJul 2015
SKINZBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBCHFJul 2015
CPPS.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDJul 2015

Biography

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 02:01
End of Day Share Price2020/01/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.